MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions.
about
Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancerMicroRNAs as growth regulators, their function and biomarker status in colorectal cancerWhat influences preneoplastic colorectal lesion recurrence?Epigenetic reduction of DNA repair in progression to gastrointestinal cancerEZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.Low miR-34a and miR-192 are associated with unfavorable prognosis in patients suffering from osteosarcoma.SATB1 and 2 in colorectal cancer.Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis.microRNA-17 Is the Most Up-Regulated Member of the miR-17-92 Cluster during Early Colon Cancer EvolutionAnalysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy.MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathwayColorectal tumor molecular phenotype and miRNA: expression profiles and prognosis.Assessment of epigenetic alterations in early colorectal lesions containing BRAF mutations.MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications.Colorectal serrated pathway cancers and precursors.Microsatellite instability: an update.Function and regulation of microRNA-31 in development and disease.Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotype-genotype correlation.Mismatch repair deficiency as a prognostic factor in mucinous colorectal cancer.Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway.Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.
P2860
Q26774690-465D599F-1F19-4976-986B-68129CB8A12AQ26775610-0289A33E-5B3A-43E0-B168-80B555054D08Q28072915-52B35DB7-FC6C-4AFB-8BE5-ED15B461E414Q28262162-C0136B75-0793-42D4-AB32-AE753FAB9CB5Q33566687-75E1535B-0F36-485E-A8E6-43CF53D4AFCAQ34487177-E5D5E6B6-7848-4B62-8D5B-0B2CA6FA0459Q35137803-3B2B5A00-3940-48BE-8B01-D0320C51B512Q35452140-50E5A637-2DDE-4B9F-BB47-82E138AFAC0CQ35740184-05317CE8-1A84-4EED-A7E7-D040EF22B039Q35806198-06274DD1-C023-49EC-9E8C-2DA497D5B1EFQ36355891-9DF68496-2F33-4C24-84CE-AA684A15E1BFQ36822387-19AB645A-1D42-487A-92F0-BA3E9E22222FQ37022273-427E4A19-7C4B-45F0-B505-8C3119906380Q37139194-E39F5A64-0392-4055-97F5-EA17DDAE8ADBQ37376477-D1F822DE-40D1-49D9-8EC4-5C64C4FACAD6Q37731180-5658B5E2-25BE-43F6-A02F-C4579E51C3F4Q38255029-02DE1DB8-6FA4-4C36-A96A-D2A927102B44Q38363519-8B6A97DE-76A1-4F66-AB52-BE09DB665FAFQ38893973-F70455AF-E0A4-46C2-83B4-0B47D0EA0228Q39514200-D1FFF3F8-7758-4DA3-B14A-B112212C6D6CQ40975682-800AC6B5-8904-4549-8864-2C53958EECE3Q41372623-6CDFE58E-30D9-46D6-AD8E-A2CC2A84F4D3Q50043586-8BAF76A0-4825-4747-9346-DB367445E680
P2860
MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
MicroRNA-31 expression in rela ...... continuum in serrated lesions.
@en
MicroRNA-31 expression in rela ...... continuum in serrated lesions.
@nl
type
label
MicroRNA-31 expression in rela ...... continuum in serrated lesions.
@en
MicroRNA-31 expression in rela ...... continuum in serrated lesions.
@nl
prefLabel
MicroRNA-31 expression in rela ...... continuum in serrated lesions.
@en
MicroRNA-31 expression in rela ...... continuum in serrated lesions.
@nl
P2093
P2860
P50
P356
P1476
MicroRNA-31 expression in rela ...... continuum in serrated lesions
@en
P2093
Eiichiro Yamamoto
Hiroaki Takahashi
Hiromu Suzuki
Hiroyuki Yamamoto
Hisayoshi Igarashi
Katsuhiko Nosho
Kei Mitsuhashi
Kohzoh Imai
Masahiro Fujita
P2860
P304
P356
10.1002/IJC.28920
P577
2014-04-30T00:00:00Z